Alzheimer’s disease (AD): investigational treatments

Evidence-based neurology checklist on alzheimer’s disease (ad): investigational treatments: Monoclonal antibodies Aducanumab Crenezumab Donanemab Gantarenumab Glucagon-like peptide 1 (GLP1) receptor agonists Other treatments

Monoclonal antibodies

  • Aducanumab
  • Crenezumab
  • Donanemab
  • Gantarenumab

Glucagon-like peptide 1 (GLP1) receptor agonists

Other treatments

References

  1. Sevigny J, Chiao P, Bussière T, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature 2016; 537:50-56.
  2. Yang T, Dang Y, Ostaszewski B, et al. Target engagement in an Alzheimer trial: Crenezumab lowers amyloid β oligomers in cerebrospinal fluid. Ann Neurol 2019; 86:215-224.
  3. Ostrowitzki S, Bittner T, Sink KM, et al. Evaluating the safety and efficacy of crenezumab vs placebo in adults with early Alzheimer disease: two phase 3 randomized placebo-controlled trials. JAMA Neurol 2022; 79:1113-1121.
  4. Tariot PN, Lopera FS, Ríos-Romenets S, et al. Safety and efficacy of crenezumab in cognitively unimpaired carriers of the PSEN1Glu280Ala mutation at risk for autosomal-dominant Alzheimer's disease in Colombia (API ADAD Colombia Trial): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2026; 25:147-159.
  5. Mintun MA, Lo AC, Duggan Evans C, et al. Donanemab in early Alzheimer's disease. N Engl J Med 2021; 384:1691-1704.
  6. And 9 more. Subscribe to see the full list

Related checklists

Loading...